Actively Recruiting
REstoring CONsciousness With NEurostimulation of the Central Thalamus: The RECONNECT Study
Led by Samuel Snider, MD · Updated on 2025-11-14
2
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The RE-CONNECT study is an early feasibility study to establish the safety, feasibility, and efficacy of two central thalamic deep brain stimulation targets in patients with chronic disorders of consciousness.
CONDITIONS
Official Title
REstoring CONsciousness With NEurostimulation of the Central Thalamus: The RECONNECT Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Central nervous system injury of any cause that happened at least 3 months before the eligibility phone call
- No daily meaningful interaction, defined as intelligible speech or ability to follow verbal commands
- Diagnosis of disorder of consciousness based on CRS-R, either Unresponsive Wakefulness Syndrome or Minimally Conscious State
- Having a documented health care proxy or court-appointed guardian
- Neurologist and neurosurgeon agree that MRI or CT shows no bilateral subcortical injury preventing electrode placement
You will not qualify if you...
- Pregnant
- Unable to have brain MRI
- Living outside the Greater Boston metropolitan area due to transportation needs
- Pre-existing psychiatric, neurological, or medical condition making surgery unsafe, such as neurodegenerative disorder or significant heart/lung disease
- Structural problems with chest wall, neck, brain, or skull that make electrode placement unsafe
- Neurologist and neurosurgeon agree that MRI or CT shows no bilateral diffuse injury to the basal ganglia
- Medical contraindications to surgery including chronic infection, blood clotting problems, poorly controlled high blood pressure with cardiovascular disease
- Participation in another drug, device, or biological trial within 90 days
- Having a current implanted stimulation device like pacemaker or deep brain stimulator
- Taking anticoagulant or anti-platelet medication that cannot be stopped safely for more than 2.5 weeks around surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
S
Samuel B Snider, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here